Product Information

ROFLUMILAST 250 MCG TABLET is a generic product labeled by Micro Labs Limited, priced at $1.5343 per EA under NDC 42571036983. Its NADAC has been published 172 times since Aug 9, 2023.

FDA first approved this application on Mar 22, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

ROFLUMILAST 250 MCG TABLET

ROFLUMILAST
$1.5343per EA

Strength

250 ug/1

Manufacturer

Micro Labs Limited

NDC

42571036983

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

ROFLUMILAST

Approval Type

Generic (ANDA)

FDA Application

ANDA208180

FDA Approved

3/22/2019

TE Code

AB

On Market Since

5/1/2023

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price Statistics

The NADAC for ROFLUMILAST 250 MCG TABLET has been published 172 times since Aug 9, 2023, and over the history we have for it it has declined 80.9%. The table below summarizes its recorded NADAC range and movement.

Current price$1.5343 per EA
All-time high$8.0346 (Aug 16, 2023)
All-time low$1.5343 (Nov 18, 2026)
52-week high$2.3109
52-week low$1.5343
Median price$2.3500
Average price$2.5665
Largest weekly change+63.4% (Aug 21, 2024)
Weeks tracked172
Tracking sinceAug 9, 2023

Price History

1W

-15.0%

1M

-22.6%

3M

-23.2%

6M

-21.3%

1Y

-33.6%

3Y

-56.2%

5Y

N/A

All

-80.9%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ROFLUMILAST market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of ROFLUMILAST 250 MCG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Micro Labs Limited, is $1.5343 per EA (NDC 42571036983), effective Nov 18, 2026.

How has the price of ROFLUMILAST 250 MCG TABLET changed over time?

Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 80.9%. It has been tracked across 172 weekly CMS publications since Aug 9, 2023.

What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?

Since Aug 9, 2023, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.5343 (Nov 18, 2026) to a high of $8.0346 (Aug 16, 2023), with a median of $2.3500 per EA.

Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of ROFLUMILAST 250 MCG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures ROFLUMILAST 250 MCG TABLET?

ROFLUMILAST 250 MCG TABLET (NDC 42571036983) is labeled by Micro Labs Limited, and CMS classifies it as a generic product.